Endocrinology, bone, rare genetic disease, acromegaly, subclinical cortisolism, low bone mass and osteoporosis diseases
56
Scopus Publications
Scopus Publications
Phosphate metabolism in primary hyperparathyroidism: a real-life long-term study Carla Columbu, Domenico Rendina, Luigi Gennari, Flavia Pugliese, Vincenzo Carnevale, Antonio Stefano Salcuni, Iacopo Chiodini, Claudia Battista, Patrizia Tabacco, Vito Guarnieri, Giuseppe Guglielmi, Cristina Eller-Vainicher, Cristiana Cipriani, Antonello Cuttitta, Gianpaolo De Filippo, Fernanda Velluzzi, Alberto Falchetti, Salvatore Minisola, Afredo Scillitani, Fabio Vescini Endocrine, 2025
Clinical and molecular description of the first Italian cohort of 33 subjects with hypophosphatasia Luigia Cinque, Flavia Pugliese, Antonio Stefano Salcuni, Domenico Trombetta, Claudia Battista, Tommaso Biagini, Bartolomeo Augello, Grazia Nardella, Francesco Conti, Sabrina Corbetta, Rita Fischetto, Thomas Foiadelli, Agostino Gaudio, Cosimo Giannini, Enrico Grosso, Gregorio Guabello, Stefania Massuras, Andrea Palermo, Luisa Politano, Francesca Pigliaru, Rosaria Maddalena Ruggeri, Emanuela Scarano, Piera Vicchio, Salvatore Cannavò, Mauro Celli, Francesco Petrizzelli, Mario Mastroianno, Marco Castori, Alfredo Scillitani, Vito Guarnieri Frontiers in Endocrinology, 2023 IntroductionHypophosphatasia (HPP) is a rare genetic disease caused by inactivating variants of the ALPL gene. Few data are available on the clinical presentation in Italy and/or on Italian HPP surveys.MethodsThere were 30 suspected HPP patients recruited from different Italian tertiary cares. Biological samples and related clinical, biochemical, and anamnestic data were collected and the ALPL gene sequenced. Search for large genomic deletions at the ALPL locus (1p36) was done. Phylogenetic conservation and modeling were applied to infer the effect of the variants on the protein structure.ResultsThere were 21 ALPL variants and one large genomic deletion found in 20 out of 30 patients. Unexpectedly, NGS-driven differential diagnosis allowed uncovering three hidden additional HPP cases, for a total of 33 HPP subjects. Eight out of 24 coding variants were novel and classified as “pathogenic”, “likely pathogenic”, and “variants of uncertain significance”. Bioinformatic analysis confirmed that all the variants strongly destabilize the homodimer structure. There were 10 cases with low ALP and high VitB6 that resulted negative to genetic testing, whereas two positive cases have an unexpected normal ALP value. No association was evident with other biochemical/clinical parameters.DiscussionWe present the survey of HPP Italian patients with the highest ALPL mutation rate so far reported and confirm the complexity of a prompt recognition of the syndrome, mostly for HPP in adults. Low ALP and high VitB6 values are mandatory for the genetic screening, this latter remaining the gold standard not only to confirm the clinical diagnosis but also to make differential diagnosis, to identify carriers, to avoid likely dangerous therapy in unrecognized cases.
Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors Renato Cozzi, Maria Rosaria Ambrosio, Roberto Attanasio, Claudia Battista, Alessandro Bozzao, Marco Caputo, Enrica Ciccarelli, Laura De Marinis, Ernesto De Menis, Marco Faustini Fustini, Franco Grimaldi, Andrea Lania, Giovanni Lasio, Francesco Logoluso, Marco Losa, Pietro Maffei, Davide Milani, Maurizio Poggi, Michele Zini, Laurence Katznelson, Anton Luger, Catalina Poiana, _ _ European Journal of Endocrinology, 2022 Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different clinical settings and always require an individually tailored approach. This is the reason why a panel of Italian neuroendocrine experts was charged with the task to provide indications for the diagnostic and therapeutic approaches that can be easily applied in different contexts. The document provides 15 recommendations for diagnosis and 54 recommendations for treatment, issued according to the GRADE system. The level of agreement among panel members was formally evaluated by RAND-UCLA methodology. In the last century, prolactinomas represented the paradigm of pituitary tumors for which the development of highly effective drugs obtained the best results, allowing to avoid neurosurgery in most cases. The impressive improvement of neurosurgical endoscopic techniques allows a far better definition of the tumoral tissue during surgery and the remission of endocrine symptoms in many patients with pituitary tumors. Consequently, this refinement of neurosurgery is changing the therapeutic strategy in prolactinomas, allowing the definitive cure of some patients with permanent discontinuation of medical therapy.
Normocalcemic primary hyperparathyroidism: An update Antonio S. SALCUNI, Claudia BATTISTA, Flavia PUGLIESE, Carla COLUMBU, Vito GUARNIERI, Vincenzo CARNEVALE, Alfredo SCILLITANI Minerva Endocrinology, 2021 Normocalcemic primary hyperparathyroidism (NPHPT) is diagnosed in the setting of elevated PTH concentrations with consistently normal albumin-adjusted and ionized serum calcium levels, in absence of secondary causes for elevated PTH concentrations. In order to confirm persistence of the hyperparathyroid state, PTH levels should be elevated on at least two occasions over a 3 to 6 months period. The prevalence of NPHPT depends on the population studied. Data from different studies are often not comparable; indeed, different criteria have been used to exclude secondary hyperparathyroidism. Notwithstanding such limits, the prevalence of NPHPT in studies including ionized calcium dosage was between 0.5% and 0.7%. Available data suggest that patients with NPHPT are likely to have more skeletal, kidney and metabolic complications compared to healthy subjects, but almost all studies suffer from possible misclassification of patients due to lack of ionized calcium dosage. The management of NPHPT is controversial in part due to lack of solid data about the natural history. However, surgical treatment is currently performed more frequently than in the past, although studies do not show, so far, a clear benefit from intervention.
Prevalence of less severe hypercortisolism in fractured patients admitted in an outpatient clinic for metabolic bone diseases F. Pugliese, A. S. Salcuni, C. Battista, V. Carnevale, G. Guglielmi, C. Columbu, F. Velluzzi, L. Giovanelli, C. Eller-Vainicher, A. Scillitani, I. Chiodini Endocrine, 2021 To evaluate the prevalence of less severe hypercortisolism (LSH) in fractured patients, and its association with hypertension, hyperglicemia, dyslipidemia, and obesity. From July 2015 to October 2018 we enrolled all fractured patients admitted in our outpatient center for metabolic bone diseases, after exclusion of patients with secondary osteoporosis apart from diabetes and taking drugs known to affect bone metabolism. In all enrolled patients we collected data regarding gonadal status, history of diabetes, high blood pressure, dyslipidemia, and measured blood pressure, lipid profile, fasting glycaemia. Bone mass was measured with DXA at lumbar spine and femoral neck and the presence of fractures was evaluated with X-ray of thoracic and lumbar spine. All patients performed twice, 1 mg overnight dexametasone suppression test (DST) and, as confirmatory, 2day low-dose DST for diagnosing hypercortisolism. We enrolled 101 fractured patients (75 females, 26 males), aged 65 ± 10.3 years. Five out of 101 (5.0%) patients were diagnosed as LSH. Fifty-five (54.5%) out of 101 were hypertensive, 57 (56.4%) dyslipidemic, 17 (16.8%) hyperglicaemic, 28(27.7%) obese patients. LSH tended to be associated to blood hypertension [5/5 vs 50/96 (Fisher exact test, p = 0.06) hypertensive patients]. Four out five LSH patients were hypogonadic. Our study confirms that a nonnegligible percentage of fractured subjects actually presents an unrecognized hypercortisolism. Accordingly, regardless of age, we suggest to screen for hypercortisolism all patients with established osteoporosis and in particular hypertensive subjects.
Treatment of acromegalic osteopathy in real-life clinical practice: The BAAC (bone active drugs in acromegaly) study Gherardo Mazziotti, Claudia Battista, Filippo Maffezzoni, Sabrina Chiloiro, Emanuele Ferrante, Nunzia Prencipe, Ludovica Grasso, Federico Gatto, Roberto Olivetti, Maura Arosio, Marco Barale, Antonio Bianchi, Miriam Cellini, Iacopo Chiodini, Laura De Marinis, Giulia Del Sindaco, Carolina Di Somma, Alberto Ferlin, Ezio Ghigo, Antonella Giampietro, Silvia Grottoli, Elisabetta Lavezzi, Giovanna Mantovani, Emanuela Morenghi, Rosario Pivonello, Teresa Porcelli, Massimo Procopio, Flavia Pugliese, Alfredo Scillitani, Andrea Gerardo Lania Journal of Clinical Endocrinology and Metabolism, 2020 Background Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. Objective To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. Study design Retrospective, longitudinal study including 9 tertiary care endocrine units. Patients and Methods Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). Results During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P < .001), duration of active acromegaly (OR 1.01; P = .04), active acromegaly at the study entry (OR 2.48; P = .007), and treated hypoadrenalism (OR 2.50; P = .005). In the entire population, treatment with bone active drugs did not have a significant effect on incident VFs (P = .82). However, in a sensitive analysis restricted to patients with active acromegaly at study entry (111 cases), treatment with bone active drugs was associated with a lower risk of incident VFs (OR 0.11; P = .004), independently of prevalent VFs (OR 7.65; P < .001) and treated hypoadrenalism (OR 3.86; P = .007). Conclusions Bone active drugs may prevent VFs in patients with active acromegaly.
Rare Somatic MEN1 Gene Pathogenic Variant in a Patient Affected by Atypical Parathyroid Adenoma Luigia Cinque, Flavia Pugliese, Celeste Clemente, Stefano Castellana, Maria Pia Leone, Danilo de Martino, Teresa Balsamo, Claudia Battista, Tommaso Biagini, Paolo Graziano, Marco Castori, Alfredo Scillitani, Vito Guarnieri International Journal of Endocrinology, 2020 Objective. Atypical parathyroid adenoma is a rare neoplasm, showing atypical histological features intermediate between classic benign adenoma and the rarest parathyroid carcinoma, whose the clinical behaviour and outcome is not yet understood or predictable. Up to date only two cases of atypical adenoma were found associated to a MEN1 syndrome, and only one was proved to carry a pathogenic variant of the MEN1 gene. Design. We report the clinical, histologic, and molecular findings of a 44-year-old woman, presenting with a histologically proved atypical parathyroid adenoma with an apparent aggressive behaviour. Methods and Results. CDC73 gene was screened at germline and somatic levels with no results. Whole exome sequencing performed on DNA extracted from blood leukocytes and tumour tissue revealed a somatic MEN1 gene heterozygous variant, c.912+1G > A, of the splicing donor site of exon 6. On immunohistochemistry, downregulation of the menin protein expression in the neoplastic cells was also observed. Conclusions. We report the second case of a rare association of a somatic MEN1 gene mutation in a patient with atypical parathyroid adenoma. We suggest that MEN1 gene could be an underestimate genetic determinant of these rare histological entities, and we highlight the utility of a complete genetic screening protocol, by the use of next-generation sequencing technology in such undetermined clinical cases with no frank clinical presentation.
Adrenal function and skeletal regulation Iacopo Chiodini, Claudia Battista, Elisa Cairoli, Cristina Eller-Vainicher, Valentina Morelli, Serena Palmieri, Antonio Stefano Salcuni, Alfredo Scillitani Multidisciplinary Approach to Osteoporosis from Assessment to Treatment, 2018 The hormones produced by the adrenal gland have important effects on the bone both in physiological and pathological conditions. The role of cortisol secretion on the bone physiology during growth is not fully understood. During the adult life, the degree of the cortisol secretion, still in the normal range, seems to directly correlate with the bone mineral density in elderly individuals and in osteoporotic women. The overt and subclinical cortisol excess leads to an increased risk of fracture partially independent of the bone mineral density reduction and possibly related to a reduced bone quality. The individual sensitivity to cortisol due to the different polymorphisms of the glucocorticoid receptor (GR) or of the 11β-hydroxysteroid dehydrogenase may modulate the effect of glucocorticoids (GCs) on the bone, thus explaining, at least in part, the wide interindividual variability of the skeletal consequences of the hypercortisolism. The adrenal androgens excess in congenital adrenal hyperplasia (CAH) importantly affects the bone, leading not only to an early growth acceleration but to a reduction in the final adult height. On the other hand, the reduction of the adrenal androgens during aging has been considered among the pathophysiological mechanisms of the osteoporosis in the elderly, but the effects of the restoration of the androgen levels in the aging-related osteoporosis are conflicting. Finally, the presence of mineralocorticoid receptors has been demonstrated in osteoblast, osteoclast, and osteocyte, and an association exists between indexes of bone strength and some genes involved in aldosterone pathways. In keeping, the condition of hyperaldosteronism has been associated with an increased fracture risk.
Primary aldosteronism as a cause of secondary osteoporosis Antonio Stefano Salcuni, Vincenzo Carnevale, Claudia Battista, Serena Palmieri, Cristina Eller-Vainicher, Vito Guarnieri, Flavia Pugliese, Giuseppe Guglielmi, Gaetano Desina, Salvatore Minisola, Iacopo Chiodini, Alfredo Scillitani European Journal of Endocrinology, 2017 Objective Patients with primary aldosteronism (PA) have a high prevalence of osteoporosis (OP) and fractures (Fx). We evaluated the presence of PA in patients admitted to our metabolic bone disease outpatient clinic. Design Study conducted on an in- and outpatient basis in a referral Italian endocrinology unit. Methods A total of 2632 patients were evaluated. 2310 were excluded because they were taking drugs known to affect bone or mineralocorticoids metabolism or were diagnosed to have a secondary cause of osteoporosis. The remaining 322 subjects (304 females, 18 males) took part in the study. Bone mineral density (BMD) and thoracic and lumbar spine vertebral morphometry were performed by dual X-ray absorptiometry. All patients were screened for PA with aldosterone-to-renin ratio. In those who had positive results, confirmatory tests were performed. Results Among 322 subjects, 213 were osteoporotics and 109 were not. PA was diagnosed in eleven out of 213 osteoporotic patients (5.2%) and one out of 109 non-osteoporotic subjects (0.9%, P = 0.066). PA was observed in the 26.1% of patients with the concomitant presence of osteoporosis, hypertension and hypercalciuria. Compared with patients without PA, patients with PA had mean values of urinary calcium excretion, 4.8 ± 2.5 mmol/day vs 7.6 ± 3.2 mmol/day, P < 0.001 and serum PTH levels, 5.4 pmol/L vs 7.3 pmol/L, P < 0.01, significantly higher. Conclusions PA should be considered among the causes of secondary OP.
MEN1 gene mutation with parathyroid carcinoma: First report of a familial case Luigia Cinque, Angelo Sparaneo, Antonio S Salcuni, Danilo de Martino, Claudia Battista, Francesco Logoluso, Orazio Palumbo, Roberto Cocchi, Evaristo Maiello, Paolo Graziano, Geoffrey N Hendy, David E C Cole, Alfredo Scillitani, Vito Guarnieri Endocrine Connections, 2017 Background The occurrence of parathyroid carcinoma in multiple endocrine neoplasia type I (MENI) is rare and the 15 cases of malignant parathyroid tumor reported so far have been associated with MENI in individuals and not with multiple members within a family. Methods We report on a 61-year-old male, operated for a 7.3 cm parathyroid carcinoma infiltrating the esophagus. In his brother, a 4.6 cm parathyroid carcinoma was diagnosed histologically, while in the daughter, neck ultrasonography revealed 2 extrathyroidal nodules, yet to be excised. Results Screening of the MEN1 gene identified a known germline heterozygous missense mutation (c.1252G>A; p.D418N) in exon 9, in all affected subjects. Conclusions The occurrence of parathyroid carcinoma in more than one affected member of a single MEN1 family represents the first reported familial case. This suggests that additional constitutional genetic mutations may contribute to the variation in malignant potential and clinical behavior of parathyroid tumors in MEN1.
Novel association of MEN1 gene mutations with parathyroid carcinoma Luigia Cinque, Angelo Sparaneo, Filomena Cetani, Michelina Coco, Celeste Clemente, Massimiliano Chetta, Teresa Balsamo, Claudia Battista, Eliana Sanpaolo, Elena Pardi, Leonardo D'Agruma, Claudio Marcocci, Evaristo Maiello, Geoffrey N. Hendy, David E.C. Cole, Alfredo Scillitani, Vito Guarnieri Oncology Letters, 2017
Vitamin D status in primary hyperparathyroidism: effect of genetic background Claudia Battista, Vito Guarnieri, Vincenzo Carnevale, Filomena Baorda, Mauro Pileri, Maria Garrubba, Antonio S. Salcuni, Iacopo Chiodini, Salvatore Minisola, Elisabetta Romagnoli, Cristina Eller-Vainicher, Stefano A. Santini, Salvatore Parisi, Vincenzo Frusciante, Andrea Fontana, Massimiliano Copetti, Geoffrey N. Hendy, Alfredo Scillitani, David E. C. Cole Endocrine, 2017
Improving adherence to and persistence with oral therapy of osteoporosis M. L. Bianchi, P. Duca, S. Vai, G. Guglielmi, R. Viti, C. Battista, A. Scillitani, S. Muscarella, G. Luisetto, V. Camozzi, R. Nuti, C. Caffarelli, S. Gonnelli, C. Albanese, V. De Tullio, G. Isaia, P. D’Amelio, F. Broggi, M. Croci Osteoporosis International, 2015
Increased prevalence of the GCM2 polymorphism, Y282D, in primary hyperparathyroidism: Analysis of three Italian cohorts Leonardo D'Agruma, Michela Coco, Vito Guarnieri, Claudia Battista, Lucie Canaff, Antonio S. Salcuni, Sabrina Corbetta, Filomena Cetani, Salvatore Minisola, Iacopo Chiodini, Cristina Eller-Vainicher, Anna Spada, Claudio Marcocci, Giuseppe Guglielmi, Michele Zini, Rosanna Clemente, Betty Y. L. Wong, Danilo de Martino, Alfredo Scillitani, Geoffrey N. Hendy, David E. C. Cole Journal of Clinical Endocrinology and Metabolism, 2014
Factors associated with vertebral fracture risk in patients with primary hyperparathyroidism Cristina Eller-Vainicher, Claudia Battista, Vito Guarnieri, Silvana Muscarella, Serena Palmieri, Antonio Stefano Salcuni, Giuseppe Guglielmi, Sabrina Corbetta, Salvatore Minisola, Anna Spada, Geoffrey N Hendy, David E C Cole, Iacopo Chiodini, Alfredo Scillitani European Journal of Endocrinology, 2014
Identification and functional characterization of three NoLS (nucleolar localisation signals) mutations of the CDC73 Gene Valerio Pazienza, Annamaria la Torre, Filomena Baorda, Michela Alfarano, Massimiliano Chetta, Lucia Anna Muscarella, Claudia Battista, Massimiliano Copetti, Dieter Kotzot, Klaus Kapelari, Dalia Al-Abdulrazzaq, Kusiel Perlman, Etienne Sochett, David E. C. Cole, Fabio Pellegrini, Lucie Canaff, Geoffrey N. Hendy, Leonardo D’Agruma, Leopoldo Zelante, Massimo Carella, Alfredo Scillitani, Vito Guarnieri Plos One, 2013
CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: Clinical correlations in a single-centre patient cohort Vito Guarnieri, Claudia Battista, Lucia Anna Muscarella, Michele Bisceglia, Danilo de Martino, Filomena Baorda, Evaristo Maiello, Leonardo D’Agruma, Iacopo Chiodini, Celeste Clemente, Salvatore Minisola, Elisabetta Romagnoli, Sabrina Corbetta, Raffaella Viti, Cristina Eller-Vainicher, Anna Spada, Michela Iacobellis, Nazzarena Malavolta, Massimo Carella, Lucie Canaff, Geoffrey N. Hendy, David E. C. Cole, Alfredo Scillitani Cellular Oncology, 2012
CASR gene activating mutations in two families with autosomal dominant hypocalcemia Vito Guarnieri, Angela Valentina D'Elia, Filomena Baorda, Valerio Pazienza, Giorgia Benegiamo, Pietro Stanziale, Massimiliano Copetti, Claudia Battista, Franco Grimaldi, Giuseppe Damante, Fabio Pellegrini, Leonardo D'Agruma, Leopoldo Zelante, Massimo Carella, Alfredo Scillitani Molecular Genetics and Metabolism, 2012
Bone involvement in aldosteronism Antonio Stefano Salcuni, Serena Palmieri, Vincenzo Carnevale, Valentina Morelli, Claudia Battista, Vito Guarnieri, Giuseppe Guglielmi, Gaetano Desina, Cristina Eller-Vainicher, Paolo Beck-Peccoz, Alfredo Scillitani, Iacopo Chiodini Journal of Bone and Mineral Research, 2012
Inhibition of cyclophosphamide mutagenicity by β-carotene Biomedicine and Pharmacotherapy, 1985
Influence of combination chemotherapy on antithrombin III activity in patients with neoplastic diseases Journal of Experimental and Clinical Cancer Research, 1985
Methylprednisolone and chlorpromazine alone or in combination for the control of cisplatin-induced emesis Cancer Treatment Reports, 1984
Clinical treatment of advanced renal cell carcinoma Journal of Experimental and Clinical Cancer Research, 1984
Possibilities and limits of chemotherapy and hepatic artery's embolization in treatment of hepatic growths Rassegna Internazionale Di Clinica E Terapia, 1983
